600165 宁科生物
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-17.169-14.124-630.484-141.042-31.724
总资产报酬率 ROA (%)-7.972-3.881-21.032-14.906-6.409
投入资产回报率 ROIC (%)-9.612-7.569-55.433-24.808-9.274

边际利润分析
销售毛利率 (%)-6.835-19.955-19.539-34.6210.084
营业利润率 (%)-46.465-24.842-162.216-172.692-39.561
息税前利润/营业总收入 (%)-41.467-29.372-125.849-130.799-25.362
净利润/营业总收入 (%)-46.789-36.648-167.102-180.357-40.912

收益指标分析
经营活动净收益/利润总额(%)64.064147.92850.91660.90792.316
价值变动净收益/利润总额(%)-0.144-215.84814.378-6.631-14.389
营业外收支净额/利润总额(%)0.77430.1053.2664.3021.567

偿债能力分析
流动比率 (X)1.9612.7720.1130.1060.153
速动比率 (X)1.2622.3610.0590.0550.087
资产负债率 (%)50.30646.34688.91789.66575.079
带息债务/全部投入资本 (%)0.281-0.16867.90059.72848.212
股东权益/带息债务 (%)19,026.338-34,638.58533.56010.18954.847
股东权益/负债合计 (%)87.827104.6723.7263.73922.748
利息保障倍数 (X)-7.735-4.761-3.008-2.634-1.710

营运能力分析
应收账款周转天数 (天)71.65467.17364.58656.53715.543
存货周转天数 (天)96.10074.04486.28795.59575.511